Literature DB >> 12766899

Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine.

Michael V Knopp1, Frederik L Giesel, Hendrik von Tengg-Kobligk, Jannis Radeleff, Martin Requardt, Miles A Kirchin, Hans-Rainer Hentrich.   

Abstract

PURPOSE: To compare intraindividually gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for multi-station MR Angiography of the run-off vessels.
MATERIALS AND METHODS: Twenty-one randomized healthy volunteers received either Gd-BOPTA or Gd-DTPA as a first injection and then the other agent as a second injection after a minimum interval of 6 days. Each agent was administered at a dose of 0.1 mmol/kg bodyweight followed by a 25-mL saline flush at a single constant flow rate of 0.8 mL/second. Images were acquired sequentially at the level of the pelvis, thigh, and calf using a fast three-dimensional (3D) gradient echo sequence. Source, subtracted source, maximum intensity projection (MIP), and subtracted MIP image sets from each examination were evaluated quantitatively and qualitatively on a segmental basis involving nine vascular segments.
RESULTS: Significantly (P < 0.05) higher signal-to-noise and contrast-to-noise ratios were noted for Gd-BOPTA compared to Gd-DTPA, with the more pronounced differences evident in the more distal vessels. Qualitative assessmentrevealed no differences in the abdominal vasculature, a preference for Gd-BOPTA in the pelvic vasculature, and markedly better performance for Gd-BOPTA in the femoral and tibial vasculature. Summation of individual diagnostic quality scores for each segment revealed a significantly (P = 0.0001) better performance for Gd-BOPTA compared to Gd-DTPA.
CONCLUSION: Greater vascular enhancement of the run-off vasculature is obtained after Gd-BOPTA, particularly in the smaller more distal vessels. Enhancement differences are not merely dose dependent, but may be due to different vascular enhancement characteristics of the agents. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766899     DOI: 10.1002/jmri.10313

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  12 in total

Review 1.  [CTA and MRA in peripheral arterial disease--is DSA out?].

Authors:  T Leibecke; C Kagel; A Lubienski; S O Peters; T Jungbluth; T Helmberger
Journal:  Radiologe       Date:  2006-11       Impact factor: 0.635

Review 2.  Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence.

Authors:  E Kanal; K Maravilla; H A Rowley
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-22       Impact factor: 3.825

3.  Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.

Authors:  H A Rowley; G Scialfa; P-y Gao; J A Maldjian; D Hassell; M J Kuhn; F J Wippold; M Gallucci; B C Bowen; I M Schmalfuss; J Ruscalleda; S Bastianello; C Colosimo
Journal:  AJNR Am J Neuroradiol       Date:  2008-07-03       Impact factor: 3.825

4.  Contrast-enhanced MR angiography: does a higher relaxivity MR contrast agent permit a reduction of the dose administered for routine vascular imaging applications?

Authors:  Xiaoying Xing; Xiangzhu Zeng; Xuan Li; Qiang Zhao; Miles A Kirchin; Gianpaolo Pirovano; Xiaoying Wang; Yuan Li; Roberto Iezzi; Francesco De Cobelli
Journal:  Radiol Med       Date:  2014-09-03       Impact factor: 3.469

5.  Comparison of gadobenate dimeglumine and gadodiamide in the evaluation of spinal vascular anatomy with MR angiography.

Authors:  M V Spampinato; S A Nguyen; Z Rumboldt
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-06       Impact factor: 3.825

6.  Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study).

Authors:  Yanjun Li; X Li; D Li; J Lu; X Xing; F Yan; Yuan Li; X Wang; R Iezzi; F De Cobelli
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-04       Impact factor: 3.825

Review 7.  [Contrast agents in MRT. Substance, effects, pharmacology and validity].

Authors:  P Reimer; R Vosshenrich
Journal:  Radiologe       Date:  2004-03       Impact factor: 0.635

8.  Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children.

Authors:  Guenther Schneider; Hellmut Schürholz; Miles A Kirchin; Arno Bücker; Peter Fries
Journal:  Pediatr Radiol       Date:  2012-11-24

9.  Follow-up of coiled cerebral aneurysms at 3T: comparison of 3D time-of-flight MR angiography and contrast-enhanced MR angiography.

Authors:  N Anzalone; F Scomazzoni; M Cirillo; C Righi; F Simionato; M Cadioli; A Iadanza; M A Kirchin; G Scotti
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-12       Impact factor: 3.825

10.  New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging.

Authors:  Ketan B Ghaghada; Murali Ravoori; Divya Sabapathy; James Bankson; Vikas Kundra; Ananth Annapragada
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.